Edition:
United States

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

5.40USD
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
$5.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,683
52-wk High
$12.35
52-wk Low
$5.10

Chart for

About

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $434.83
Shares Outstanding(Mil.): 79.06
Dividend: --
Yield (%): --

Financials

  ADRO.OQ Industry Sector
P/E (TTM): -- 97.68 30.58
EPS (TTM): -1.21 -- --
ROI: -23.44 3.30 12.84
ROE: -42.91 2.30 15.02

BRIEF-Aduro Biotech Q1 Loss Per Share $0.28

* Q1 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Aduro Announces Milestone Achieved Under Merck Collaboration

* ADURO ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF ANTI-CD27 PHASE I TRIAL IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Aduro Biotech Promotes Hans Van Eenennaam In Its Europe Unit

* ADURO BIOTECH APPOINTS HANS VAN EENENNAAM EXECUTIVE VICE PRESIDENT ANTIBODY RESEARCH AND SITE HEAD, ADURO BIOTECH EUROPE Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Aduro Biotech Q4 Loss Per Share $0.34

* ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

Earnings vs. Estimates